-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
FibroGen, Inc. (NASDAQ:FGEN) Sees Large Decline in Short Interest
FibroGen, Inc. (NASDAQ:FGEN) Sees Large Decline in Short Interest
FibroGen, Inc. (NASDAQ:FGEN – Get Rating) was the target of a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 4,950,000 shares, a drop of 9.2% from the July 15th total of 5,450,000 shares. Currently, 5.8% of the company's shares are sold short. Based on an average trading volume of 971,600 shares, the days-to-cover ratio is presently 5.1 days.
Institutional Investors Weigh In On FibroGen
Several hedge funds and other institutional investors have recently made changes to their positions in FGEN. Nisa Investment Advisors LLC increased its holdings in FibroGen by 369.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,795 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 2,200 shares during the last quarter. Quantbot Technologies LP purchased a new position in FibroGen during the second quarter valued at $39,000. Dixon Hughes Goodman Wealth Advisors LLC bought a new stake in FibroGen during the first quarter valued at about $59,000. Lazard Asset Management LLC bought a new position in shares of FibroGen in the second quarter worth about $59,000. Finally, Advisor Group Holdings Inc. lifted its position in shares of FibroGen by 90.6% during the 4th quarter. Advisor Group Holdings Inc. now owns 8,909 shares of the biopharmaceutical company's stock valued at $130,000 after buying an additional 4,236 shares in the last quarter. Hedge funds and other institutional investors own 77.35% of the company's stock.
Get FibroGen alerts:FibroGen Stock Performance
Shares of NASDAQ:FGEN remained flat at $14.44 on Wednesday. The stock had a trading volume of 11,717 shares, compared to its average volume of 653,054. The company has a market capitalization of $1.35 billion, a P/E ratio of -6.05 and a beta of 0.87. The business has a 50 day moving average price of $11.91 and a 200 day moving average price of $11.98. FibroGen has a 1 year low of $7.81 and a 1 year high of $16.91.
FibroGen (NASDAQ:FGEN – Get Rating) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.16. FibroGen had a negative net margin of 83.64% and a negative return on equity of 100.51%. The firm had revenue of $29.81 million for the quarter, compared to the consensus estimate of $36.15 million. During the same quarter in the prior year, the firm posted ($1.45) earnings per share. The business's revenue was up 22.3% on a year-over-year basis. On average, equities analysts anticipate that FibroGen will post -3 EPS for the current year.Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the company. The Goldman Sachs Group decreased their target price on FibroGen from $9.00 to $8.00 and set a "sell" rating for the company in a report on Tuesday, May 24th. Cowen increased their target price on FibroGen to $14.00 in a research report on Monday. Finally, StockNews.com lowered FibroGen from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th.
About FibroGen
(Get Rating)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
See Also
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Agilent Technologies Proves Its Worth VS Illumina
- Lowe's Stands Out Amid Q2 Retail Reports
- Target's Results Cap Upside Potential For Retail Stocks
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
FibroGen, Inc. (NASDAQ:FGEN – Get Rating) was the target of a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 4,950,000 shares, a drop of 9.2% from the July 15th total of 5,450,000 shares. Currently, 5.8% of the company's shares are sold short. Based on an average trading volume of 971,600 shares, the days-to-cover ratio is presently 5.1 days.
FibroGen,Inc.(纳斯达克:FOGEN-GET评级)是空头股数7月份大幅下跌的目标。截至7月31日,空头股数共有495万股,较7月15日的545万股减少了9.2%。目前,该公司5.8%的股票被卖空。以971,600股的平均成交量计算,目前的天数与回补比率为5.1天。
Institutional Investors Weigh In On FibroGen
机构投资者对FibroGen的看法
Several hedge funds and other institutional investors have recently made changes to their positions in FGEN. Nisa Investment Advisors LLC increased its holdings in FibroGen by 369.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,795 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 2,200 shares during the last quarter. Quantbot Technologies LP purchased a new position in FibroGen during the second quarter valued at $39,000. Dixon Hughes Goodman Wealth Advisors LLC bought a new stake in FibroGen during the first quarter valued at about $59,000. Lazard Asset Management LLC bought a new position in shares of FibroGen in the second quarter worth about $59,000. Finally, Advisor Group Holdings Inc. lifted its position in shares of FibroGen by 90.6% during the 4th quarter. Advisor Group Holdings Inc. now owns 8,909 shares of the biopharmaceutical company's stock valued at $130,000 after buying an additional 4,236 shares in the last quarter. Hedge funds and other institutional investors own 77.35% of the company's stock.
几家对冲基金和其他机构投资者最近改变了他们在fgen的头寸。NISA Investment Advisors LLC在第二季度增持了369.7%的FibroGen股份。NISA Investment Advisors LLC现在拥有2,795股这家生物制药公司的股票,价值30,000美元,在上个季度又购买了2,200股。Quantbot Technologies LP在第二季度购买了FibroGen的一个新头寸,价值3.9万美元。Dixon Hughes Goodman Wealth Advisors LLC在第一季度购买了FibroGen的新股份,价值约5.9万美元。Lazard Asset Management LLC在第二季度购买了FibroGen的新头寸,价值约5.9万美元。最后,Advisor Group Holdings Inc.在第四季度将其在FibroGen的股票头寸提高了90.6%。Advisor Group Holdings Inc.现在持有这家生物制药公司8,909股股票,价值13万美元,上个季度又购买了4,236股。对冲基金和其他机构投资者持有该公司77.35%的股票。
FibroGen Stock Performance
FibroGen股票表现
Shares of NASDAQ:FGEN remained flat at $14.44 on Wednesday. The stock had a trading volume of 11,717 shares, compared to its average volume of 653,054. The company has a market capitalization of $1.35 billion, a P/E ratio of -6.05 and a beta of 0.87. The business has a 50 day moving average price of $11.91 and a 200 day moving average price of $11.98. FibroGen has a 1 year low of $7.81 and a 1 year high of $16.91.
周三,纳斯达克股价持平于14.44美元。该股成交量为11,717股,而其平均成交量为653,054股。该公司市值13.5亿美元,市盈率为-6.05,贝塔系数为0.87。该业务的50日移动均线价格为11.91美元,200日移动均线价格为11.98美元。FibroGen的一年低点为7.81美元,一年高位为16.91美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
A number of equities analysts recently commented on the company. The Goldman Sachs Group decreased their target price on FibroGen from $9.00 to $8.00 and set a "sell" rating for the company in a report on Tuesday, May 24th. Cowen increased their target price on FibroGen to $14.00 in a research report on Monday. Finally, StockNews.com lowered FibroGen from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th.
一些股票分析师最近对该公司发表了评论。高盛夫妇将FibroGen的目标价从9.00美元下调至8.00美元,并在5月24日周二的一份报告中为该公司设定了“卖出”评级。考恩在周一的一份研究报告中将FibroGen的目标价上调至14.00美元。最后,StockNews.com在8月10日星期三的一份研究报告中将FibroGen的评级从“买入”下调至“持有”。
About FibroGen
关于FibroGen
(Get Rating)
(获取评级)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen,Inc.是一家生物制药公司,发现、开发和商业化治疗严重未得到满足的医疗需求的疗法。该公司正在开发一种口服低氧诱导因子Pro羟基酶小分子抑制剂roxadustat,该药已在美国、欧洲、中国和日本完成了治疗慢性肾脏疾病贫血的第三阶段临床开发,并在中国完成了治疗与骨髓增生异常综合征相关的贫血的第二/第三阶段临床开发。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Agilent Technologies Proves Its Worth VS Illumina
- Lowe's Stands Out Amid Q2 Retail Reports
- Target's Results Cap Upside Potential For Retail Stocks
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- 免费获取StockNews.com关于FibroGen的研究报告(Fgen)
- 安捷伦科技对Illumina证明了自己的价值
- Lowe‘s在第二季度零售报告中脱颖而出
- 塔吉特的业绩上限零售类股的上行潜力
- 这3只电子游戏股票现在还在玩吗?
- 2辆长期电动汽车的交易价格低于20美元
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对FibroGen和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧